ArticleBritish journal of pharmacology2007
Neuroprotection with or without erythropoiesis; sometimes less is more.
Article in British journal of pharmacology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 15 citations in OpenAlex.
- Recombinant Erythropoietin Induces Oligodendrocyte Progenitor Cell Proliferation After Traumatic Brain Injury and Delayed Hypoxemia.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023Article
- Erythropoietin regulates signaling pathways associated with neuroprotective events.Experimental brain research · 2022Review
- Erythropoietin-derived peptide treatment reduced neurological deficit and neuropathological changes in a mouse model of tauopathy.Alzheimer's research & therapy · 2021Article
- The erythropoietin-derived peptide MK-X and erythropoietin have neuroprotective effects against ischemic brain damage.Cell death & disease · 2017Article
- Carbamylated Erythropoietin: A Prospective Drug Candidate for Neuroprotection.Biochemistry insights · 2015Review
- Apoptosis induced by parasitic diseases.Parasites & vectors · 2010Article
- Erythropoietin promotes neurological recovery after intracerebral haemorrhage in rats.International journal of stroke : official journal of the International Stroke Society · 2009Article
- Article
- Pharmacological approaches to acute ischaemic stroke: reperfusion certainly, neuroprotection possibly.British journal of pharmacology · 2008Review
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erythropoietin (EPO) is a pleiotropic cytokine with a therapeutic potential that goes well beyond the treatment of anaemia. The study by Wang et al (2007b) examined the protective effects of EPO in a rat model of embolic stroke. The efficacy and haematological side effects of EPO were compared to those of a carbamylated EPO variant (CEPO). Treatment with EPO dose-dependently reduced infarct volume and improved long-term functional outcome. However, an increase in hematocrit was seen even for doses of EPO that did not offer neuroprotection. These data do not suggest the existence of a therapeutic window between effect and side effect for treatment with EPO. Treatment with CEPO was without haematological side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.